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Introduction
Medicaid is a major source of payment for prescription drugs. In 2002, the last year for
which sufficiently detailed data are available, Medicaid programs and Medicaid managed care
plans spent an estimated $29.7 billion for prescribed drugs. Prescribed drugs are one of the
most often used and fastest growing Medicaid services. Over 26 million Americans received at
least one drug paid for by Medicaid in the year 2000, and data indicate that the number of
prescriptions paid for by Medicaid – and presumably the number of recipients – increased
considerably in more recent years.
Most Medicaid payments for prescribed drugs (80% in 2000) are for drugs consumed by
enrollees age 65 and older and younger persons with disabilities, but these individuals (9 million
in 2000) account for only a third of drug recipients in Medicaid (34% in 2000). Utilization is also
highly skewed, so a small percentage of enrollees accounts for a large majority of utilization and
payments. The highest cost users tend to be older enrollees and data suggest that they
generally have one or more chronic conditions. However, even among those with the highest
drug costs, prescribed drugs tend to account for no more than one third of total health care
payments.
A majority of the aged and disabled individuals who currently receive drugs paid for by
Medicaid are also eligible for Medicare. Spending for these dual eligibles is also highly skewed.
The top 20% of dual eligibles, as ranked by per capita outpatient drug payments, accounted for
nearly two-thirds (64%) of all spending for outpatient drugs provided to dual eligibles in 2000.
Starting in 2006, federal matching funds will no longer be available to states for Medicaid
drug coverage provided for all full-benefit dual eligibles, a provision that presumably will shift
this population into the newly created Medicare drug benefit (Part D). It is unclear what effect
the shift to Part D will have on this group in terms of accessibility of drugs and out of pocket
costs. Also, while a Medicare drug benefit might have saved states a large amount of money,
states will not realize most of these potential savings because they will have to contribute
toward the cost of Part D by returning most of their savings to the federal government. Medicaid
will continue to provide prescription drug coverage to other enrolled populations.

Background
Medicaid is a joint federal-state program that pays for medical assistance for individuals
and families with low incomes and relatively few assets. Two key roles of the program are to
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act as a major source of coverage for health care services for low-income children, caretaker
relatives and people with disabilities, and to provide long-term care for older individuals and
younger people with disabilities. During federal fiscal year (FFY) 2002 the Medicaid program
enrolled an estimated 50.8 million people, with states and the federal government spending an
estimated total of $257.6 billion.1
Although it is an optional benefit under federal Medicaid law, all states currently provide
coverage for outpatient prescription drugs to all categorically eligible individuals and most other
enrollees within their Medicaid programs.2 The bulk of Medicaid prescription drug spending is
for elderly and disabled enrollees, including many who are also eligible for Medicare. Medicaid
has been a key source of coverage for these “dual eligibles” in the absence of a Medicare drug
benefit.
States opting to cover prescribed drugs are required to cover all drugs approved by the
Food and Drug Administration (FDA) that are made by manufacturers that have entered into a
federal rebate agreement.3 In exchange, states receive rebates based on formulae established
in federal law. Beyond this requirement, states retain significant autonomy over the design of
their prescription drug benefits. For example, they can limit the duration (e.g., number of doses)
and scope (e.g., total number) of prescriptions, require substitution for brand name drugs with
generic equivalents, or make coverage of medications subject to prior authorization. States can
also establish a formulary or preferred drug list (PDL) as long as the design process meets
federal requirements and any excluded drugs are available through prior authorization. Lastly,
states set the levels at which they reimburse pharmacies for drug products and the dispensing
fees paid to pharmacists. Although this paper focuses on national data, there is considerable
variation in Medicaid drug coverage, expenditures and utilization across states.
Three broad characteristics determine the level of spending for prescribed drugs in any
public or private program: the quantity of drugs consumed (e.g., total units), the mix of drugs
consumed (e.g., branded vs. generic), and the price per unit of each drug. Although studies
often disagree over the extent to which each of these factors drove increased spending in
Medicaid and other markets, it is generally agreed that all three factors played a role. The
volume of prescriptions and number of prescriptions per user has increased since the early
1990s. Increased use has been attributed to many factors, including improved insurance
coverage, population aging, increased diagnosis of chronic conditions, new drugs that treat a
wide range of diagnoses, new markets opened by these new drugs, greater emphasis on
pharmaceuticals in medical practice, and growth of direct-to-consumer advertising.4 The unit
price for medications has increased as new drugs enter the market at higher prices and prices
for existing drugs rise, while the mix of drugs consumed also has shifted to newer, more costly
drugs.5 This shift has been attributed to many factors including (but not limited to) demonstrated
or professed advantages of new medications, the effect of advertising on consumer awareness
and demand, and low insurance copayments that may make people less sensitive to prices.6

Data Sources and Methods
Most data in this report are the authors’ estimates based on data from the Centers for
Medicare and Medicaid Services (CMS). We draw information from several data sets compiled
by CMS to serve different purposes: expenditures from the Quarterly Medicaid Statement of
Expenditures for the Medical Assistance Program (Form CMS-64), prescription utilization and
reimbursement information from the Medicaid Drug Rebate Program, and person-level eligibility
and payment data from the Medicaid Statistical Information System (MSIS). These sources

2

contain somewhat different measures of drug spending which may lead to slight variations in
estimates of total drug spending, even for the same period. We identify the source of each
estimate within the text and/or at the bottom of each figure.
The spending figures in this analysis reflect spending for outpatient drugs – that is, those
purchased from pharmacies. These figures include drugs for individuals in provider settings
where Medicaid pays for drugs separately from other expenses (such as room and board), as is
the case with nursing home residents in most states.7 Expenditures for drugs provided as part
of a course of treatment in a hospital or physician’s office are not included in our estimates.
Some figures include estimated spending for prescribed drugs by health maintenance
organizations (HMOs) and other managed care entities serving Medicaid enrollees. To estimate
prescription drug utilization and spending within managed care plans, we use a reweighting
simulation that assumes that managed care beneficiaries have drug utilization similar to that of
fee-for-service beneficiaries with similar characteristics. We then estimate utilization patterns
and payments for this simulated managed care population. Additional information about our
sources and the process by which we estimated managed care spending is provided in the
Appendix.

Trends in Medicaid Drug Expenditures and Utilization
Medicaid expenditures for outpatient prescribed drugs totaled an estimated $29.7 billion
in federal fiscal year 2002.8 Drugs paid for by Medicaid on a fee-for-service basis accounted for
$23.4 billion (80%) of this total, net of $5.9 billion in rebates from manufacturers required by the
federal Medicaid Drug Rebate Program and additional rebates negotiated by states.9 However,
millions of Medicaid participants are enrolled in managed care plans where the plan pays for
their outpatient prescribed drugs. We estimate that managed care plans paid $6.3 billion for
outpatient prescribed drugs for Medicaid enrollees in 2002.

Figure 1
Medicaid Expenditures for Outpatient
Prescribed Drugs, Including Drugs Provided by
Managed Care Plans, 1992-2002

$29.7

$30

Expenditures (billions)

Prescribed drugs are one of the
fastest-growing expenses for Medicaid.
Expenditures for prescribed drugs
doubled between 1998 and 2002, and
they have quadrupled since 1992
(Figure 1). The share of Medicaid
spending attributable to prescribed
drugs also grew in recent years. In
1998, less than eight percent of
Medicaid expenditures were for
outpatient prescribed drugs; by 2002,
this share climbed to over 11 percent
(Figure 2). Between 2000 and 2002,
expenditures for prescribed drugs (feefor-service only) increased by an
average of 18.8 percent per year, faster
than any other major type of Medicaidcovered service (Figure 3).
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Source: Urban Institute estimates based on data from MSIS and Form CMS-64.
Note: Data are for federal fiscal years (October-September). Fee-for-service drug expenditures are net of rebates.
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Rapid growth of drug
expenditures is not limited to
Medicaid. CMS’ actuaries estimate
that prescription drug spending by
private insurers grew by an
average of 17.4 percent per year
between 1999 and 2002,
comparable to 18.0 percent in
Medicaid (Table 1). On a per
person basis, drug spending by
private insurers may even be rising
faster than Medicaid drug
expenditures, as enrollment in
private insurance fell between
1999 and 2002 while participation
in Medicaid increased.12

Figure 2
Expenditures for Outpatient Prescribed Drugs as
a Share of Total Medicaid Spending, 1992-2002
11.6%
10.9%
10.1%

12%

Share of Total Spending

Medicaid increasingly has
become a key source of payment
for prescribed drugs, accounting
for an estimated 17.5 percent of all
personal health care expenditures
for drugs in 2002, or more than $1
out of every $6 spent.10 It is also a
rapidly growing segment of states’
Medicaid programs, and they have
implemented a number of cost
control mechanisms in recent
years in an effort to rein in rapidly
growing prescription drug
expenditures.11
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Source: Urban Institute estimates based on data from Form CMS-64 and the Medicaid Statistical
Information System (MSIS).
Note: Data are for federal fiscal years (October-September). Percentages are net of drug rebates.

Figure 3
Average Annual Growth of Fee-for-Service Medicaid
Expenditures for Selected Services, 2000-2002
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Source: Urban Institute estimates based on data from Form CMS-64.
Note: Rates represent average annual growth in total expenditures made on a fee-for-service basis for the types of
services listed. The rate shown for managed care reflects growth in payments to health plans, which cover a wide
range of services including prescribed drugs.

Table 1

Growth in Personal Health Care Expenditures and Spending for
Prescription Drugs, 1999-2002
Average Annual Growth
of Expenditures for…
All
Personal
Health Care

Prescribed
Drugs
Only

Total Payments

8.0%

Private Insurance
Medicaid

Prescribed Drugs as a
Share of All Personal
Health Care Expenditures
1999

2002

15.9%

9.8%

12.0%

9.4%

17.4%

13.1%

16.2%

10.2%

18.0%

10.0%

12.2%

Source: Centers for Medicare & Medicaid Services (CMS), Office of the Actuary, National
Health Statistics Group
Note: Years shown are calendar years.
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Growth in Medicaid prescription drug spending is partly due to more prescriptions being
filled for enrollees. Based on drug utilization data from the Medicaid Drug Rebate Program, we
estimate that Medicaid paid for approximately 430 million prescriptions in 2000 and over 525
million in 2002 on a fee-for-service basis – that is, excluding prescriptions paid for by managed
care plans.13 These figures translate to a 10 percent average annual increase in the number of
prescriptions paid for by Medicaid.

Enrollees (millions)

A contributing factor to the rise in overall utilization is an increase in Medicaid enrollment
and, presumably, the number of drug recipients. After a brief decline in late 1990s, the number
of enrollees began to increase in 1999
and grew significantly after 2000 (Figure
Figure 4
4). This growth has been attributed to a
Medicaid Enrollment, 1995-2003
combination of eligibility expansions
60
enacted by states in the 1990s and the
52.4
50.9
50
economic downturn of the early 2000s,
44.6
44.2
41.3
40.6
41.7
41.1
40.4
which lowered incomes and made more
40
people eligible at all eligibility levels.14
30
Data on the number of drug recipients in
Medicaid are not available after 2000, but
20
if one assumes that the percentage of
10
enrollees receiving at least one
prescribed drug has not decreased, then
0
1995 1996 1997 1998 1999 2000 2001* 2002* 2003*
recent enrollment increases would
logically increase the number of
Sources: Values for 1995-2000 are Urban Institute estimates based on data from Form HCFA-2082 and the
Medicaid Statistical Information System (MSIS); values for 2001-2003 estimates from Congressional Budget
recipients.
Office baselines produced in March 2002, 2003, and 2004.
Note: “Enrollees” defined as all individuals who sign up for Medicaid at any point in time during the federal fiscal
year. This estimate is larger than the number of persons enrolled at any single point in time during the year.

It is likely that the average
number of prescribed drugs consumed
by each recipient in Medicaid is increasing, but available data do not allow us to observe the
number of prescriptions or drug units that each Medicaid enrollee uses. Studies of the U.S.
civilian noninstitutionalized population and individuals in private health plans indicate that the
number of people taking at least one prescribed drug has increased, as has the average
number of prescriptions per user.15 Assuming that physicians use similar prescribing patterns
for Medicaid enrollees as they do for other patients, these trends likely carry over to Medicaid.

The average cost of drugs paid for by Medicaid is increasing. Based on data from the
Medicaid Drug Rebate Program, we estimate that the average reimbursement for outpatient
prescribed drugs increased from about $49 per prescription in 2000 to $57 in 2002 – a rise of
roughly 8 percent per year and more than 16 percent over the two-year period.16 Although
these estimates exclude drugs paid for by managed care plans, fee-for-service payments
account for most Medicaid expenditures for prescribed drugs. We could not determine the
extent to which these price increases reflect changes in the mix of drugs consumed or general
price increases.

A Closer Look at Medicaid Drug Utilization and Spending
In this section, we look more closely at the populations that receive prescribed drugs
through Medicaid and the types of drugs that they use. We rely on data from the year 2000
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because it is the most recent year for which we have access to data with sufficient detail to
observe utilization and spending for specific groups of Medicaid enrollees.
Prescribed drugs are one of the most often used Medicaid services. Data from CMS
indicate that about 20.5 million individuals (out of 44.3 million enrollees) received a drug paid for
by Medicaid in 2000, and that total payments for these drugs were about $20 billion. However,
the 20.5 million recipients do not include drug recipients in Medicaid managed care plans except
where the drug benefit is carved out.17 Likewise, the $20 billion total payments do not include
payments made by managed care plans or savings from the Medicaid Drug Rebate Program.18
Including individuals in managed care plans, we estimate that Medicaid paid for at least one
outpatient prescribed drug (i.e., a drug dispensed by a pharmacy) for approximately 26.6 million
individuals in 2000, or about 62 percent of all Medicaid enrollees. Total payments for prescribed
drugs, adjusted to reflect payments made by Medicaid managed care plans and drug rebates,
were about $20.2 billion in 2000.19
There are significant differences in prescription drug use and payments among Medicaid
enrollees. Enrollees age 65 and older and younger persons with disabilities were 34 percent of
all drug recipients in 2000, but 80 percent of payments for prescribed drugs were attributable to
these groups (Table 2).
Table 2

Drug Recipients and Payments by Group, 2000

Total

Dual Eligibles
Aged

Disabled

Other Aged
& Disabled

Adults

Children

5.6 million

3.4 million

2.2 million

3.4 million

5.5 million

12.1 million

21%

13%

8%

13%

21%

46%

$10.5 billion

$5.4 billion

$5.1 billion

$5.4 billion

$2.0 billion

$2.1 billion

52%

27%

25%

28%

10%

10%

$1,880

$1,590

$2,350

$1,670

$360

$170

Drug Recipients
Number
Percent of Total

Payments for Prescribed Drugs
Amount
Percent of Total
Payments per Recipient
Average for Group

Source: Authors’ estimates based on data from the Medicaid Statistical Information System (MSIS)
Notes: Includes estimates of recipients enrolled in managed care plans and drug payments by those plans. Average payments per
recipient for each group are rounded to the nearest $10 increment.

Although not shown in Table 2, nonelderly disabled enrollees (duals and non-duals)
accounted for more payments for drugs than all other eligible groups combined. In contrast,
adults and children were 65 percent of drug recipients but accounted for 20 percent of total
payments for prescribed drugs. Significantly higher average payments per recipient for aged
and disabled recipients indicate that these individuals are much more likely to consume greater
numbers of prescriptions for longer periods of time than adults and children (Table 2).
We further estimate that about 5.5 million prescription drug recipients in Medicaid in
2000 were dual eligibles, for whom Medicaid pays the bulk of drug costs in the absence of a

6

Medicare drug benefit (Table 2). According to earlier Urban Institute estimates, roughly 5.84
million Medicaid enrollees were “full” dual eligibles in 2000; that is, Medicare participants who
were eligible for the full range of Medicaid benefits.20 Combined, these two estimates suggest
that 95 percent of “full” dual eligibles receive at least one prescription paid for by Medicaid.
Such a high level of utilization is not surprising, given that studies have consistently found lower
health status and greater service use among dual eligibles. Relatively high levels of utilization
are also reflected by the share of total payments for prescribed drugs attributable to dual
eligibles, which we estimate at 52 percent (Figure 5).
Figure 5
Distribution of Medicaid Drug Payments for
Dual Eligibles and Other Enrollees, 2000
Adults and
Children
20%

Other Aged
and Disabled
28%

Dual Eligible,
Aged
27%

Dual Eligible,
Disabled
25%

Total Drug Payments = $20.2 billion
Source: Urban Institute estimates based on data from the Medicaid Statistical Information System (MSIS).

Drug utilization is skewed such that a small percentage of Medicaid enrollees accounts
for a large share of total drug payments. One analysis by Pharmaceutical Research and
Manufacturers of America (PhRMA) indicates that among individuals who participated in
Medicaid for any length of time in 2000, the highest drug spenders21 used an average of 41
prescriptions (new and refill) during the year while all other Medicaid participants had an
average of four.22 The PhRMA analysis includes every drug used throughout the year and not
just those paid for by Medicaid, but drug payment data indicate that use is highly skewed within
Medicaid. Limiting our analysis to enrollees without payments to managed care plans, we
observed that the top 20 percent of enrollees (ranked by Medicaid payments for prescribed
drugs, including individuals with no drug payments) accounted for 90 percent of total payments
for prescribed drugs in 2000 (Table 3).23 Average payments for prescribed drugs were $3,100
for the top 20 percent of drug spenders and only $80 for the remaining 80 percent of enrollees.
The distribution of total payments is also highly skewed within each eligible group, although
most high-cost individuals come from the aged and disabled populations (Table 3).
While the distribution of spending for prescription drugs is skewed toward high cost
users, even among the highest-cost users drugs account for a relatively modest share of total
payments for medical services. Across the entire fee-for-service population, average payments
for drugs for the top spenders were $3,100 but average payments for medical services (drugs
and all other services) were $14,610 in 2000. In contrast, average drug payments for the
remaining 80 percent of recipients were $80 and average total payments for this group were
$2,200 (Table 3).
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Table 3
Distribution of Fee-for-Service Medicaid Payments for Outpatient Prescribed Drugs, 2000
Distribution of Outpatient Drug Payments,
Top 20% of Drug Spenders vs. All Others

Distribution of Outpatient Drug Payments
for the Top 20% of Drug Spenders

10%

9%

Dual Eligible,
Aged

Top Spenders
All Others

34%

90%

Distribution of Outpatient Drug Payments for
Dual Eligible, Aged Enrollees (Age 65+)

Top Spenders

59%

All Enrollees
$650
$4,560

Top 20% of
Aged Duals
$4,450
$19,790

Adults and
Children

Top Spenders
$3,100
$14,610

All Others
$80
$2,200

Distribution of Outpatient Drug Payments for
Dual Eligible, Disabled Enrollees
Under Age 65

Top Spenders

32%

All Others

68%

All Others

Average Payments per Enrollee for…

Average Payments per Enrollee for…

Prescribed Drugs
All Medicaid

Other Aged or
Disabled

25%

Average Payments per Enrollee
Outpatient Prescribed Drugs
All Medicaid

41%

Dual Eligible,
Disabled

32%

All Other
Aged Duals
$740
$8,430

Distribution of Outpatient Drug Payments for
Other Aged & Disabled Enrollees

All Other
Top 20% of
Disabled Duals Disabled Duals
Prescribed Drugs
$8,100
$900
All Medicaid
$22,030
$8,840
Distribution of Outpatient Drug Payments for
Nondisabled Adults and Children

12%
26%

Top Spenders

Top Spenders

74%

All Others

All Others

Average Payments per Enrollee for…
Top 20% of
All Other
Non-Dual Aged Non-Dual Aged
and Disabled
and Disabled
Prescribed Drugs
$6,180
$520
All Medicaid
$23,980
$7,440

88%

Average Payments per Enrollee for…

Prescribed Drugs
All Medicaid

Top 20% of
Adults and
Children
$650
$3,520

All Other
Adults and
Children
$20
$970

Source: Authors’ estimates based on data from the Medicaid Statistical Information System (MSIS).
Notes: Estimates are for individuals with no reported payments made to HMOs (or, in a few states, prepaid health plans). “Top
spenders” are defined as the top 20 percent of enrollees ranked by total drug payments. “All others” are the remaining 80
percent of individuals, including individuals with no reported drug payments. Payments for prescribed drugs are for outpatient
prescribed drugs; generally, these are drugs purchased at a retail pharmacy, but also include most drugs purchased for
residents of nursing facilities. Generally, drugs provided as a course of treatment in a hospital, physician’s office or other
provider setting are not reflected here.
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Percentage of Enrollees

Enrollees who account for the most payments for prescription drugs tend to be older.
Enrollees age 65 and older accounted for 15 percent of the fee-for-service Medicaid population
in 2000, but were 41 percent of top
spenders (Figure 6). Enrollees
Figure 6
age 45 to 64 were 10 percent of
Age
Distribution
of
Fee-for-Service
Enrollees, Top
the population, but 27 percent of
Drug Spenders vs. All Others, 2000
top spenders. Enrollees under age
45 were 75 percent of the fee-for100%
9%
service population, but they
80%
23%
44%
accounted for just 32 percent of
52%
Ages 0 to 17
top spenders. Although not shown
60%
Ages 18 to 44
27%
in Table 3 or Figure 6, we also
Ages 45 to 64
31%
40%
observed that higher cost
Ages 65 and Up
33%
enrollees tended to be among the
41%
20%
10%
oldest people in each category;
6%
15%
9%
that is, higher shares of “top
0%
All
Enrollees
Top
Spenders
for
All
Others
spenders” in the nondisabled adult
Prescribed Drugs
and disabled groups were age 45
Source: Urban Institute estimates based on data from the Medicaid Statistical Information System (MSIS).
Note: Estimates are for individuals with no reported payments made to HMOs (or, in a few states, prepaid health
to 64 and average drug spending
plans). “Top spenders” are defined as the top 20 percent of enrollees ranked by total drug payments. “All others”
are the remaining 80 percent of individuals, including individuals with no reported drug payments.
for people age 75 and older was
higher than for people age 65 to
74.
According to the aforementioned PhRMA study, Medicaid enrollees with high drug
spending are much more likely to have serious chronic conditions than the rest of the Medicaid
population. The most common chronic disease diagnoses among these individuals are
essential hypertension, “other nontraumatic joint disorders,” diabetes, “other mental conditions”
including depression, asthma and “other upper respiratory disease,” and lipid (fat/cholesterol)
disorders. Many individuals have multiple diagnoses.24
Medicaid drug utilization data indicate that drug classifications that accounted for the
largest numbers of prescriptions and drug payments in 2000 are generally those used to treat
diagnoses highlighted by PhRMA (Table 4). Antihypertensives, ace inhibitors, antianginals,
calcium channel blockers and diuretics are all used to treat hypertension (high blood pressure)
and other cardio-pulmonary disorders. Nonsteroidal anti-inflammatory drugs (NSAIDs),
including newer COX-2 inhibitors, are used for arthritis and other joint disorders. Blood glucose
regulators are used to manage diabetes. Anti-anxiety drugs, anticonvulsants, antidepressants,
anitmanics and antipsychotics are prescribed for mental conditions. Antiasthmatics and
bronchodilators treat asthma and other lung diseases. A large majority of reimbursements
within each of these high-use, high reimbursement classes (those in the top panel of Table 4)
tends to be attributable to newer, typically brand name drugs. For example, newer drugs
collectively known as selective serotonin reuptake inhibitors (SSRIs) accounted for most
reimbursements for antidepressants in 2000, and newer COX-2 inhibitors accounted for the vast
majority of NSAID reimbursements.
High use drug classes that were not among those with the most reimbursements reflect
Medicaid’s role as insurer for millions of individuals, especially nondisabled adults and children,
whose demand for drugs centers around more short-term, acute illnesses. These include drugs
for acid/peptic disorders (e.g., ulcers), analgesics (for pain relief), antihistamines (for allergies),
penicillins (for internal bacterial infections), dermatologics (for external fungal infections), and
estrogens/progestins (includes drugs used as contraceptives and treatments for osteoporosis,
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menopause, certain cancers and blood ailments). Many of these classifications include large
numbers of drugs with multiple brand name and generic competitors.
In contrast, table 4 also lists five high reimbursement classes that are not high use.
Hyperlipidemia drugs (for fat/cholesterol disorders) and lincosamides/macrolides (for bacterial
infections) fell just shy of our cutoff for inclusion on the highest use list, but make it on the high
reimbursement list due to higher costs per prescription relative to other high use classes such
as antihistamines and penicillins. Antivirals appear on the high reimbursement list because of
several drugs primarily used in the treatment of HIV/AIDS with very high per-unit costs.

Table 4
Drug Classifications with the Highest Total Use and
Reimbursement in Medicaid, 2000
(Listed Alphabetically)

Most Prescriptions and Highest Reimbursement
(Classifications Appearing on Both Lists)
Ace Inhibitors
Acid/Peptic Disorders
Analgesics–General
Analgesics–Narcotic
Antianginals
Antianxiety
Antiasthmatics/Broncodilators
Anticonvulsants
Antidepressants
Antihypertensives
Antipsychotics/Antimanics
Blood Glucose Regulators
Calcium Channel Blockers
Estrogens/Progestins
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
Most Prescriptions Only

Highest Reimbursement Only

Anithistamines
Dermatologics
Diuretics
Electrolyte/Water Regulation
Penicillins

Anticoagulants/Thrombolytics
Antivirals
Gastrointestinal
Hyperlipidemia
Lincosamides/Macrolides

Source: Authors’ analysis of State Medicaid Drug Utilization Data from CMS.
Note: Classes are from the Food and Drug Administration (FDA) National Drug
Code directory. Drugs can fall into more than one class. This table counts all
prescriptions and reimbursements for individual drugs under every class listed by
the FDA for that drug.

Implications of the Medicare Drug Benefit
The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 (P.L.108173) established a new, voluntary drug benefit for Medicare beneficiaries, Part D of Medicare,
beginning in January 2006.25 According to previous Urban Institute estimates, there were about
7.2 million dual eligibles in Medicaid in 2002 and most (85%) qualified for full Medicaid benefits,
including prescribed drugs.26 Once Part D begins, federal funding will no longer be available for
Medicaid prescription drug coverage for dual eligibles. Most dual eligibles are expected to sign
up for Part D; however, the impact of the change in coverage from Medicaid to Medicare for
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dual eligibles is impossible to predict given the lack of specific information about design and
exact cost of Medicare drug plans, which have yet to be developed.
Medicaid programs spent an estimated $13.1 billion in combined federal and state funds
for prescribed drugs for dual eligibles in 2002; states’ shares totaled $5.6 billion, about 6 percent
of all state dollars spent on Medicaid.27 Part D will not eliminate states’ drug expenditures for
dual eligibles. Instead, states will be required to pay Medicare a share of the estimated amount
that they would have spent on drugs for dual eligibles in the absence of Part D—a requirement
sometimes called the “clawback” provision. This provision will reduce potential savings to
states, and there is chance that individual states could end up paying more drug coverage for
dual eligibles under Part D than they would have spent otherwise.

Conclusion
Medicaid is a major source of payment for prescription drugs and, like other public and
private third-party payers, its expenditures for prescribed drugs have increased quite rapidly in
recent years. Growth in Medicaid drug expenditures has been fostered by greater utilization,
which is attributable to more people eligible to receive drugs and more prescriptions per user, as
well as higher costs for drugs consumed. Increased use and higher costs are not limited to
Medicaid and affect most public and private payers.
Within Medicaid, most payments for prescribed drugs are for enrollees age 65 and older
and younger persons with disabilities, and many of the highest cost individuals are older and
have one or more serious chronic conditions. Over half of the aged and disabled individuals
who receive drugs paid for by Medicaid are dual eligibles (5.5 million individuals in 2000).
States will pay for prescribed drugs for dual eligibles through Medicaid until January 2006 and
will continue to fund this population through the Medicare Part D clawback after that date.
In addition to sharing the costs of Part D, states will continue to provide drug coverage
through Medicaid for aged and disabled individuals who do not qualify for Medicare. In 2000,
this group accounted for 3.4 million drug recipients (13% of total recipients) and $5.4 billion of
Medicaid drug payments (28% of total). Medicaid also will continue to pay for prescription drugs
for millions of nondisabled adults and children (17.7 million recipients in 2000; 20% of total
payments). Therefore, Medicaid will remain a major source of payment for prescribed drugs for
the foreseeable future and, like other public and private third-party payers, states will likely
continue to seek ways to limit their costs while protecting the needs of the vulnerable
populations that they serve.

Brian Bruen prepared this paper while he was a Research Associate at the Urban Institute. Arunabh Ghosh is
a Research Assistant at the Urban Institute.
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Appendix
Data Sources
Most data in this report are the authors’ estimates based on administrative data from the
Centers for Medicare and Medicaid Services (CMS). We rely on data from several different
data sources maintained by CMS, including expenditures from the Quarterly Medicaid
Statement of Expenditures for the Medical Assistance Program (Form CMS-64), prescription
utilization and reimbursement information from the Medicaid Drug Rebate Program, and personlevel files containing eligibility information and aggregated payments reported through the
Medicaid Statistical Information System (MSIS). CMS compiles all of these data sets
independently to serve different purposes. The net result is that, while they provide valuable
insights into the Medicaid drug benefit, each source contains different measures of spending for
prescription drugs and drug utilization.
We use Form CMS-64 data primarily to estimate expenditures for prescription drugs and
other services over time. Our source data are most comparable to state-level Medicaid
Financial Management Reports posted on the CMS Web site. Prescription drug expenditures
reported on Form CMS-64 reflect all claims for prescribed drugs that were paid during each
quarter of the federal fiscal year, as well as adjustments to reflect overpayment/underpayment
in that quarter or earlier fiscal years. Data also include separate measures of mandatory drug
rebates from federal agreements and additional rebates from state-specific agreements. We
generally report expenditures for prescribed drugs net of these rebates. The utility of Form
CMS-64 is limited because it only measures aggregate spending by state and type of service,
and there is no breakdown for various eligibility groups.
To look more closely at the distribution of spending across groups of eligible persons –
for example, in Table 2 – we use data from the Medicaid Statistical Information System (MSIS).
These data include payments by Medicaid for drugs and other services on an individual basis.
Payments for prescribed drugs reflect all claims adjudicated during the fiscal year, which can
differ from “actual” expenditures as reported on Form CMS-64. Other differences may occur
due to differences between how states acquire and report data for MSIS and Form CMS-64.
Drug payments in MSIS also reflect the level of spending for drugs prior to rebates, so we make
adjustments to account for rebates to be comparable with estimates based on Form CMS-64.
Our access to MSIS is currently limited to data for federal fiscal years 1999 and 2000.
A last important data source for this report is State Drug Utilization Data available from
the CMS Web site. These data are drawn from information collected by CMS to administer the
Medicaid Drug Rebate Program. They include measures of the total number of prescriptions
and total units reimbursed by Medicaid in each state for individual drugs, identified by National
Drug Code (NDC). This source also includes the total amount reimbursed to pharmacists for
the drug. By linking these data with information from the National Drug Code Directory from the
Food and Drug Administration, we were able to sort drugs into therapeutic/pharmacological
classes. Data quality is difficult to assess, but results were generally consistent with our
expectations. Total reimbursement levels for most states were comparable to spending levels
observed in our other sources, although our tabulations of total prescriptions and average
reimbursement per prescription reflect adjustments where we noticed significant differences in
states’ total drug reimbursements in the utilization data compared to measures of total drug
spending from Form CMS-64 and MSIS or where the reported number of prescriptions was
clearly too low or too high based on other observable measures.
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Estimating Drug Recipients and Payments Within Medicaid Managed Care Plans
All of the data sources discussed above have one common “flaw.” All measures of drug
utilization and spending for prescribed drugs in these sources exclude utilization by individuals
enrolled in Medicaid managed care plans and payments for these drugs by those plans, except
in a few instances where states “carve out” their drug benefit and continue to pay for drugs on a
fee-for-service basis. We wanted to get a sense for the total number of people who receive at
least one outpatient prescribed drug paid for by Medicaid, plus the total amount that Medicaid
and contracted managed care plans spend for these drugs. By not measuring use and
spending within managed care plans, our sources underestimate Medicaid’s role as a provider
of and payer for prescribed drugs.
To estimate prescription drug utilization and spending within managed care plans, we
use a reweighting simulation that assumes that managed care beneficiaries have drug utilization
similar to that of fee-for-service beneficiaries with similar characteristics. The simulation
exercise reweights the FFS population, on whom we have utilization data, so that it looks like
the managed care population in size and characteristics, and then estimates utilization patterns
on this simulated managed care population.
On a randomly drawn 5% sample of MSIS records, we first estimate state-specific (logit)
models of the probability of being a managed care enrollee. Independent variables include
basic demographic information (age, sex, race), eligibility category, indicators for any nursing
facility or home health use and a set of state dummies. Based on these results, we can
calculate the predicted probability that each person is a managed care enrollee based on their
independent variables. Then for each FFS enrollee, a weight is calculated based on their
predicted probability of being a managed care enrollee. Persons with higher managed care
probabilities get higher weights, while persons with lower probabilities get lower weights. The
weights are “normalized” so that they add up to the total number of managed care enrollees,
and new drug utilization estimates are calculated. This technique allows for predicted utilization
to vary among managed care enrollees in the same way it varies among FFS enrollees, so that
distributional characteristics can also be estimated for the managed care population.
From the predicted values in the 5% sample, we calculated ratios of drug recipients to
enrollees for individuals in managed care plans and individuals in fee-for-service arrangements
for each state and enrolled group, as well as the level of drug payments by managed care plans
relative to payments for people in fee-for-service arrangements. In general, we applied the
same ratios calculated from the 5% sample to the entire MSIS data set (state by state) to get
the estimates shown in this report. In a few states with very high levels of managed care this
process produced unrealistic estimates, which we adjusted to more plausible levels based on
observed recipient and payment levels from states with lower managed care penetration.
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